Profil
Masayuki Kobayashi is Chairman at Taiho Oncology, Inc. since 2014, President & Representative Director at Taiho Pharmaceutical Co., Ltd. since 2012, and Director at Otsuka Holdings Co., Ltd. since 2017.
Formerly, Mr. Kobayashi was Chief Executive Officer at Otsuka America, Inc.
Postes actifs de Masayuki Kobayashi
| Sociétés | Poste | Début |
|---|---|---|
| OTSUKA HOLDINGS CO., LTD. | Directeur/Membre du Conseil | 30/03/2017 |
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops oncology drugs | President | 03/04/2012 |
Taiho Oncology, Inc.
Taiho Oncology, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of orally administered anti-cancer agents for tumor types | Président | 01/04/2014 |
Anciens postes connus de Masayuki Kobayashi
| Sociétés | Poste | Fin |
|---|---|---|
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company whose subsidiaries manufactures and sells pharmaceutical, nutraceutical products & consumer markets | President | 31/03/2012 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops oncology drugs | Commercial Services |
Otsuka America, Inc.
Otsuka America, Inc. Pharmaceuticals: MajorHealth Technology Operates as a holding company whose subsidiaries manufactures and sells pharmaceutical, nutraceutical products & consumer markets | Health Technology |
Otsuka Holdings Co., Ltd.
Otsuka Holdings Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as an investment holding company with interests in pharmaceutical preparations | Health Technology |
Taiho Oncology, Inc.
Taiho Oncology, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of orally administered anti-cancer agents for tumor types | Health Technology |
















